HMGA1 as a prognostic biomarker for gliomas: expression patterns, survival correlations, and clinical insights from a Pakistani cohort
- 28 April 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 173 (3) , 655-666
Abstract
Purpose High-Mobility Group A1 (HMGA1) is a chromatin-associated protein involved in regulating key cellular processes, including DNA transcription, replication, recombination, and repair. It is highly expressed during embryogenesis and reactivated in various cancers, where it contributes to tumor progression and metastasis. We investigated the prognostic significance of HMGA1 gene expression in gliomas by comparing its expression in normal brain tissue and different glioma grades. Methods Real-time quantitative PCR (qPCR) was performed on 75 glioma samples obtained from Aga Khan University Hospital (Pakistan), along with 10 Normal Adjacent Tissue (NAT) samples. The correlation between HMGA1 expression and prognosis was evaluated using Kaplan–Meier (KM) plotter in glioma patients. Statistical analyses were conducted using the R platform and further validated through the online database Chinese Glioma Genome Atlas (CGGA) using online tools. Results HMGA1 expression was significantly upregulated in gliomas compared to NAT (p < 0.001) and increased with tumor grade (p = 0.015). High HMGA1 expression correlated with Ki-67 levels and was associated with worse survival (p = 0.0014). Patients with elevated HMGA1 had a 3.5-fold higher mortality risk (95% CI: 1.5–7.9, p = 0.003). ROC analysis yielded an AUC of 0.752, indicating its potential prognostic value. Conclusion HMGA1 overexpression is associated with poor prognosis in gliomas, suggesting its potential as a prognostic marker. However, further validation is needed to confirm its clinical utility.Keywords
Funding Information
- Higher Education Commision, Pakistan (Higher Education Commission (Ref No. 20-16919/NRPU/R&D/HEC/2021))
This publication has 29 references indexed in Scilit:
- Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and TreatmentAdvanced Science, 2020
- An Integrative Model of Cellular States, Plasticity, and Genetics for GlioblastomaCell, 2019
- HMGA1 Overexpression is Associated With the Malignant Status and Progression of Breast CancerThe Anatomical Record, 2018
- Glioblastoma: Defining Tumor NichesTrends in Cancer, 2015
- HMGA1/HMGA2 protein expression and prognostic implications in gastric cancerInternational Journal of Surgery, 2015
- Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancerMolecular and Cellular Biochemistry, 2015
- Overcoming the blood–brain tumor barrier for effective glioblastoma treatmentDrug Resistance Updates, 2015
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialThe Lancet Oncology, 2014
- HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesisJournal of Neuro-Oncology, 2011
- Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancerCancer Genetics and Cytogenetics, 2004